Single-center study shows that gene expression profiling predicts melanoma recurrence and outcomes in specific stages, indicating targeted surveillance strategies.
Our data show GEP remains a robust predictor of recurrence and MSS after adjusting for clinicopathologic factors overall but is not predictive for all outcomes in stage-stratified analyses, particularly Stage II disease. Stage IA patients should forgo GEP altogether testing due to its futility in this population. Older patients with low-risk GEP may be candidates for avoidance of SLNB given lower positivity rates. GEP Class 2B patients represent a relatively high-risk population regardless of SLNB status.
No takes yet. Share an insight, caveat, or question.
Gehle et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: